Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New After-Laser cream could speed up skin recovery

NCT ID NCT06336135

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a special cream can reduce redness, swelling, and pain after laser skin treatment. Eleven adults each had four small areas treated with laser, then different creams were applied. Participants rated their symptoms daily for two weeks. The goal was to find a better way to recover from laser therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

11 people

The number who actually took part.

Started

Mar 2024

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Subjects are healthy adults receiving laser skin rejuvenation therapy.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or Female * Age: ≥18 and ≤60 years * Any skin tone Fitzpatrick score 1-2 (light), 3-4 (medium), 5-6 (dark) * Competent and willing to provide written, informed consent to participate in all study activities Exclusion Criteria: * Pregnant women * Are participating/have participated in another interventional clinical trial in the last 30 days which may confound the results of this study, unless approved by Sponsor * Use of retinoids 7 days prior to the procedure * Active cutaneous infections in the treatment area * Diseases that could inhibit healing, such as scleroderma, or other cutaneous conditions that could confound study results * Subjects unable to communicate with the investigator and staff * Any health condition that in the investigator's opinion should preclude participation in this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Skin aging are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Rejuuv Medi Spa

    Markham, Ontario, L3R0M3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.